FARMAKOLOGI - PowerPoint PPT Presentation

1 / 22
About This Presentation
Title:

FARMAKOLOGI

Description:

FARMAKOLOGI BEBAN STUDI = 3 SKS ... Hormon & Uterotonika ... To know drug effect To know drug Interaction To know spectrum drug respons MECHANISM OF ACTION : ... – PowerPoint PPT presentation

Number of Views:647
Avg rating:3.0/5.0
Slides: 23
Provided by: WURLINA
Category:

less

Transcript and Presenter's Notes

Title: FARMAKOLOGI


1
  • FARMAKOLOGI
  • BEBAN STUDI 3 SKS
  • Kuliah 2 SKS dan Praktikum 1 SKS
  • Dosen Pengasuh 5 Orang
  • GBPP ?SAP yang telah disepakati terdiri dari
  • 1. Farmakologi Umum (4 jam)
  • 2. Obat ANS Relaksasi otot (6 jam)
  • 3. Obat Anestesi lokal umum (4 jam)
  • 4. Obat Diuretik (2 jam)
  • 5. Obat Sedatif-Hipnotik CNS Stimulan (2 jam)
  • 6. Obat Analgesik, antipiretik antiinflamasi
    (2 jam)
  • 7. Obat Hemostatika (2 jam)
  • 8. Hormon Uterotonika (2 jam)
  • 9. Histamin dan Antihistamin (2 jam)

2
  • Pembobotan Penilaian Mata Kuliah
  • 1. Tugas bobot 1,5 13,64
  • 2. Kuis/tentamen dll bobot 1,5 13,64
  • 3. Soft skill bobot 1 9,09
  • 4. UTS bobot 2 18,8
  • 5. UAS bobot 3 27,27
  • 6. Praktikum bobot 2 18.18
  • bobot 11 100
  • Presensi Wajib kuliah
  • Nilai E minimal 75
  • Nilai D,C BC minimal 50

3
  • PRAKTIKUM (1 SKS)
  • GBPP ? SAP disepakati 6 materi praktikum
  • 1. Cara pemberian obat
  • 2. Obat yg berpengaruh thd. Tekanan darah
  • 3. Mengenal stadium anestesi umum
  • 4. Obat yg berpengaruh pada Diuresis
  • 5. Obat menurunkan rasa nyeri
  • 6. Obat penghambat inflamasi.
  • Presensi Wajib Praktikum 100
  • Kelompok Praktikum ? Dibagi 6 kelompok
  • A1 dari kelas A nomor urut 1-45
  • A2 dari kelas A nomor urut 46-69
  • B1 dari kelas B nomor urut 1-55
  • B2 dari kelas B nomor urut 56-70
  • C dari kelas C dan
  • D dari kelas D

4
GENERAL PHARMACOLOGY
  • BY
  • D.K. Meles

5
  • PHARMACOLOGY
  • PHARMACON Drug/ Poison
  • LOGOS Science
  • PHARMACOLOGY Science to Study of drug
  • DRUG All of substance to influence life system
    ? application to prevent,
    diagnostic and therapeutics
  • SCOPE OF PHARMACOLOGY -?
  • PHARMACOKINETIC
  • PHARMACODYNAMIC
  • PHARMACOTHERAPEUTIC
  • PHARMACOGNOSI
  • TOXICOLOGY

6
  • DRUG ? All of Substance to influence life process
    in use to prevent, therapeutics and diagnostic of
    disease.
  • Have criterion
  • 1. Effectiveness Rivesible effect
  • 2. Savety (Margin of savety) ?
  • Therapeutics Index.
  • 3. High Selectivity

7
  • PHARMACOKINETIC
  • ABSORPTION
  • DISTRIBUTION
  • BIOTRANSFORMATION
  • EXCRETION

8
  • ABSORPSI OBAT Moving Process or to remove of
    drug from tissue to another tissue ? to cross the
    membrane with spesific mechanism.
  • TRANSPORT PASIVE? Different Concentration, No
    need Energy, non spesific
  • DIFFUSION? NON-IONIC
  • FILTRATION ? POROUS
  • FASCILITATIVE DIFFUSION ? CARRIER
  • TRANSPORT ACTIVE? OPPOSITION GRADIENS
    CONCENTRATION, Need Energy Spesificity
  • 3. PINOSITOSIS/ EXOSITOSIS/ ENDOSITOSIS.

9
  • DRUG ABSORBTION ? Account in from drug dose
  • DRUG BIOAVAILABILITY? Prosentage drug to reach
    site of action. Was count from dose of drug (for
    drug sistemik only).
  • FACTOR2 TO INFLUENCE RATE OF DRUG ABSORBTION
  • 1. Route of drug application
  • 2. Circulation of place application drug.
  • 3. Solubelity of drug
  • 4. Ionization Rate of Drug
  • 5. Broad of absorbtion area.
  • 6. Size of molecule particle of drug
  • 7. Drug Formulation

10
  • ROUTE OF DRUG ADMINISTRATION
  • 1. ENTERAL (SUBLINGUAL, PER-ORAL, PER-ANAL)
  • 2. PARENTERAL (SC., IM., IV., INTRAPERITONEAL)
  • 3. TOPICAL (SKIN, MUCOSA)
  • 4. PERINHALATION.
  • Sub-Lingual
  • Condition ? Iritation, Damage by gastric Acid
  • Damage from drug metabolis.To clause
    ?
  • Dilute in saliva, Non-iritan
    Lipofilik.

11
  • PER-ORAL
  • General, easy, safety and cheap.
  • Influenced by GIT motility
  • Absorbtion ? Diffusi pasive, depend on rate of
    disolution disintegration.
  • No application in consciousless.
  • PER-RECTUM
  • Applicated in condition gastric iritation,
    vomiting, damage by gastric acid.
  • Rate of absorbtion irreguler, Sometimes rectum
    irritation

12
  • Per-injection
  • Benefid Quick in absorbtion, vomit condition
    consciousless and emergency applicated
  • Wickedness must be sterilzation, cant self
    uses, pain, ralative more expensive.
  • Intra-Vena
  • No absorbtion process ? direct in blood
  • Onset dan Duration ? quickly
  • Iritatif drug can applicated
  • Drug toxicity ? Low in therapeutics Index
  • Must be carefully

13
  • Intra-muskuler (I.M.) dan Sub-kutan (S.C.)
  • Condition non-iritan drug, water soluble or
    suspention form.
  • Quick in effect (imSc).
  • Intraperitoneal
  • In animal experimental applicated only? opten
    infection.
  • Subtitute i.v. route
  • Per-inhalation
  • Use in gas form drug.
  • Absorbtion a cross epithel mucosa quick.
  • Need tools/ specific methode
  • Dificult in dose count
  • Topical ? Unguentum, drops for mocosa skin

14
  • DRUG DISTRBUTION
  • AFTER ABSORBTION ?
  • Extracelluler Fluids (Plasma 4,Interstesiil
    13).
  • DRUG ? Protein plasma bound, Inactivation/
    metabolism process,
  • ? Bound in reseptor? Respon/ drug effect,
  • ? Exretion ? Renal
  • Intraseluler Fluid 41
  • DRUG ? Reseptor ? drug respons
  • ? Prot. tissue. ? Non Spesific
    Reversibel. ? Bound in Fat ? Drug Reservoir.
  • ? Metabolism (Biotransformation).
  • Drugs lipid soluble? easy a cross membrane and
    distribution to intracelluler fluids,
  • distribusi ke intraseluler.
  • Opposite on non lipid soluble drug

15
  • BIOTRANSFORMATION
  • MECHANISME TO CHANGE DRUGS STRUCTURE TO BE
  • Decrease in fat solublelity
  • to break in ionized
  • Decrease in protein plasm/ tissue
    bound.
  • Biotransformation ? Drug to be in active
  • Metabolite Aktive
  • Prontosil (In vitro) ? Sulfanilamid.
  • Proguanil ? Metabilite aktif.

16
  • MECHANISME OF BIOTRANSFORMATION
  • DRUG
  • ABSORBTION


  • DISTRIBUSTION? protein bound


  • reseptor bound


  • Excretion

  • BIOTRANSFORMATION

  • (metabolism)
  • FASE I FASE II
  • Oksidation? cytochrom axidase 1.
    Sulfation? Sulfonyl transferase
  • Reduction? Declorinasi 2.
    Glucorhonidation? G.transferase
  • 3. Hidrolysis?Esterase, Amidase 3.
    Conjugation? As.Glukoronat
  • 4. Hydrasi? Hidrolase
    4. AcetYlation, Methylation
  • BM lt 300 BMgt
    300 BMlt 300

17
  • PHARMAKODYNAMIC
  • Pupose To know drug effect
  • To know drug Interaction
  • To know spectrum drug respons
  • MECHANISM OF ACTION
  • Interaction with drug reseptor ? to change
    biochemical Physiological process (
    Neurotransmitter)? Respons.
  • Physical-chemist Characteristic of drug ? Drug
    respons
  • Chelating Agent ? drug respons
  • Drug incorporation with celluler structure ? drug
    respon

18
  • DRUGS INTERACTION
  • SYNERGISM ? ADITIVE POTENTIATIVE
  • ANTAGONISM
  • A. Chemist Heparin X Protamin
  • A. Functional/Physiological ( NE X Histamin)
  • A. Selective ? Receptor Drugs.
  • A. Selective Competitive In seem
    receptor.
  • Riversible ACH x Atropin
  • Irreversible NE x Prazosin
  • A. Selective non-competitive ? Different
    receptor,
  • D-R bound cant break in highly dose.
  • Papaverin x Histamin ( Papaverin x ACH)

19
  • DOSE measure / quantity of drug to give for
    individual until a cross activity threshold but
    cant cross Toxicity threshold.
  • Margin Of safety LD50 ED50
  • INFLUANCE FACTOR OF DOSE
  • BODY WEIGHT( BW)
  • OLD
  • RUST
  • SeX
  • Time of administration
  • Patological Disholder
  • Genetic factor
  • Tolerance

20
  • DRUG TOXICITY
  • Wrong in drug administration Tetracycline (I.V)
    ? konvulsive. Penicilline (I.V.) ? Presipitation.
  • To remain the drug effect ( Excessive dose/ Over
    dose, Ren liver malfunction, genetic factor,
    drug interaction).
  • Hypersensitive reaction (Allergy) Dermatitis,
    Asthma, Shyok anafilactic, damage in liver ren,
    damage in bonemarrow.
  • Blood discrasia, as well as Leucopenia, aplastic
    anaemia, haemolytic anaemia, thrombositopenia.
  • Toxicity in liver ren
  • Teratogenic effect.

21
  • RESEARCH OF DRUG
  • TO INVENTION THE NEW DRUG ?
  • EMPERICALLY
  • RASIONALITY
  • UNEXPECTED (KEBETULAN)
  • SCREENING PROCESS
  • 2. PREKLINIK TRIAL ?
  • Activity Test Side effect Test
  • Uji Pharmacokinetic dan Pharmacodynamic
  • Uji Farmacy yang meliputi
  • Uji Kualitative dan Kuantitative bahan
  • Uji Stability
  • Uji Sifat Physic dan Chemist
  • Uji drug formulation
  • Uji general toxicity Uji Acute , Sub Acute
    Chronic Toxicity Test
  • Uji specific toxicity Uji Teratogenic,
    Mutagenic dan Carcinogenic

22
SEMOGA BERMANFAAT
Write a Comment
User Comments (0)
About PowerShow.com